4D Molecular Therapeutics (FDMT) Price-to-Earnings (P/E) Ratio
Price: $3.34
Market Cap: $154.65M
Avg Volume: 827.34K
Market Cap: $154.65M
Avg Volume: 827.34K
Country: US
Industry: Biotechnology
Sector: Healthcare
Industry: Biotechnology
Sector: Healthcare
Price-to-Earnings (P/E) Ratio Summary
4D Molecular Therapeutics's P/E ratios across different time periods:
- TTM: -1.12
- Annual: -1.87
- Quarterly: -1.51
What is P/E Ratio?
The Price-to-Earnings (P/E) ratio is a valuation metric that compares a company's stock price to its earnings per share (EPS). It indicates how much investors are willing to pay for each dollar of company earnings.
Related Metrics
- Price-to-Book (P/B) Ratio: 0.59
- Price-to-Sales (P/S) Ratio: 8120.72
Annual Ratios
4D Molecular Therapeutics Historical P/E Ratio
Historical P/B Ratio
Historical P/S Ratio
TTM P/E Ratio
-1.12
P/B Ratio (Annual)
0.59
P/S Ratio (Annual)
8120.72
4D Molecular Therapeutics Historical Valuation Metrics
The table below shows various valuation metrics for each year, with the latest data available for the last fiscal year 2024.
| Year | P/E Ratio | P/B Ratio | P/S Ratio |
|---|---|---|---|
| 2024 | -1.87 | 0.59 | 8120.72 |
| 2023 | -7.86 | 2.58 | 38.26 |
| 2022 | -7.11 | -2.28 | 229.63 |
| 2021 | -8.91 | -2.94 | 33.73 |
| 2020 | -19.56 | 4.31 | 81.25 |
| 2019 | -20.27 | -14.70 | 153.59 |
| 2018 | -53.08 | -18.38 | 35.88 |
| 2017 | -53.54 | -30.67 | 103.77 |
Related Metrics
Explore detailed financial metrics and analysis for FDMT.